STOCK TITAN

Arcutis Biotherapeutics (ARQT) CEO sells 4375 shares to cover RSU taxes

(Moderate)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Arcutis Biotherapeutics President and CEO Todd Watanabe sold 4375.0000 shares of common stock on August 3, 2026 at a weighted average price of $26.1168 (with individual prices from $25.72 to $26.69) to cover tax withholding obligations arising from the vesting of Restricted Stock Units, in a transaction reported under a Rule 10b5-1 trading plan. After this sale he directly held 717203.0000 shares, including 823 acquired through the Employee Stock Purchase Plan, and additional shares are held indirectly through trusts and Watanabe Ventures, LLC, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Watanabe Todd
Role See Remarks
Sold 4,375 shs ($114K)
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 4,375 $26.1168 $114K
holding Common Stock F4 -- -- --
holding Common Stock F5 -- -- --
holding Common Stock F6 -- -- --
holding Common Stock F7 -- -- --
Holdings After Transaction: Common Stock — 717,203 shares (Direct); Common Stock — 175,776 shares (Indirect, By Trust); Common Stock — 57,358 shares (Indirect, By LLC)
Footnotes (7)
  1. F1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
  2. F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. F3. Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
  4. F4. The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
  5. F5. The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
  6. F6. The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
  7. F7. The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Shares sold 4375.0000 shares Common stock sale on August 3, 2026 to cover RSU tax withholding
Weighted average sale price $26.1168 per share Shares sold in multiple transactions at prices from $25.72 to $26.69
Direct holdings after sale 717203.0000 shares Common stock directly held by Todd Watanabe following the August 3, 2026 sale
Indirect LLC holdings 57358.0000 shares Common stock held of record by Watanabe Ventures, LLC
ESPP shares included 823 shares Shares purchased under the Employee Stock Purchase Plan on May 31, 2026
Restricted Stock Units financial
"to cover tax withholding obligations in connection with the vesting of Restricted Stock Units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Employee Stock Purchase Plan financial
"Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
weighted average sale price financial
"The price reported in Column 4 is a weighted average sale price"
pecuniary interest financial
"disclaims beneficial ownership of such securities except to the extent of his pecuniary interest"
beneficial ownership financial
"shall not be deemed an admission of beneficial ownership of such securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did ARQT CEO Todd Watanabe report?

Todd Watanabe reported a sale of 4375.0000 ARQT common shares on August 3, 2026. The sale was to cover tax withholding tied to vesting Restricted Stock Units and was reported under a Rule 10b5-1 trading plan.

At what price were the 4375.0000 ARQT shares sold by the CEO?

The shares were sold at a weighted average price of $26.1168 per share. Individual sale prices ranged from $25.72 to $26.69, with the transactions aggregated into the reported weighted average figure.

How many ARQT shares does CEO Todd Watanabe hold after this transaction?

Following the sale, Todd Watanabe directly held 717203.0000 shares of Arcutis Biotherapeutics common stock. This total includes 823 shares purchased under the company’s Employee Stock Purchase Plan on May 31, 2026.

Why did the ARQT CEO sell 4375.0000 shares of common stock?

The filing states the sale represents shares sold to cover tax withholding obligations from the vesting of Restricted Stock Units. This characterizes the transaction as tax-related rather than a discretionary portfolio adjustment.

Does the ARQT CEO have additional indirect share holdings?

Yes. Additional ARQT shares are held through family trusts and Watanabe Ventures, LLC. Watanabe disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, as described in the footnotes.

What does the Rule 10b5-1 indication mean for this ARQT insider trade?

The filing’s Rule 10b5-1 checkbox indicates the transaction was made under a pre-arranged trading plan. Such plans are designed to execute trades automatically, reducing the significance of trade timing as a signal of insider sentiment.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Watanabe Todd

(Last)(First)(Middle)
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD, SUITE 300

(Street)
WESTLAKE VILLAGE CALIFORNIA 91361

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/03/2026S(1)4,375D$26.1168(2)717,203(3)D
Common Stock25,410IBy Trust(4)
Common Stock25,410IBy Trust(5)
Common Stock57,358IBy LLC(6)
Common Stock124,956IBy Trust(7)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
4. The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
5. The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
6. The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
7. The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Remarks:
Reporting Person's title: President and Chief Executive Officer
/s/ Latha Vairavan, as Attorney-in-Fact for Todd Franklin Watanabe08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)